Upgrading Public Health Programs for Human Papillomavirus Prevention and Control is Possible in Low- and Middle-income Countries

Vaccine

Volumn 30, Issue SUPPL.5, 2012, Pages

  Steben, Marc ^a   Jeronimo, Jose ^b   Wittet, Scott ^b   LaMontagne, D Scott ^b   Ogilvie, Gina ^c   Jensen, Christina ^d   Smith, Jennifer ^e   Franceschi, Silvia ^f  

^a INSTITUT NATIONAL DE SANTÉ PUBLIQUE DU QUÉBEC   (Canada)

^b PATH   (United States)

^c BRITISH COLUMBIA CENTRE FOR DISEASE CONTROL   (Canada)

^d HEALTH CANADA   (Canada)

^e UNIVERSITY OF NORTH CAROLINA   (United States)

^f INTERNATIONAL AGENCY FOR RESEARCH ON CANCER   (France)

Author keywords

HPV prevention Cervical cancer Screening Immunization Surveillance Communication

Indexed keywords

CANCER PREVENTION; CANCER SCREENING; CONDYLOMA ACUMINATUM; CYTOLOGY; HEALTH CARE FACILITY; HEALTH CARE MANAGEMENT; HEALTH CARE PERSONNEL; HEALTH CARE QUALITY; HEALTH EDUCATION; HEALTH PROMOTION; HEALTH SERVICE; HUMAN; HUMAN PAPILLOMAVIRUS DNA TEST; HUMAN PAPILLOMAVIRUS TYPE 11; HUMAN PAPILLOMAVIRUS TYPE 6; IMMUNE RESPONSE; IMMUNIZATION; INDIA; INFORMATION TECHNOLOGY; PERU; PREDICTIVE VALUE; PREVENTION AND CONTROL; PRIORITY JOURNAL; QUALITY CONTROL; REVIEW; RURAL AREA; SCREENING TEST; SECONDARY PREVENTION; SENSITIVITY AND SPECIFICITY; SEXUAL INTERCOURSE; SEXUALLY TRANSMITTED DISEASE; THAILAND; UGANDA; UTERINE CERVIX CANCER; VIET NAM; WART VIRUS;

EID: 84877049355     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2012.06.031     Document Type: Review

References (50)

1. The Gavi Alliance. Human papillomavirus vaccine support. Available at: http://www.gavialliance.org/support/nvs/human-papillomavirus-vaccinesupport/(last accessed January 2012).
2. RHO Cervical Cancer. Available at: http://www.rho.org/index.htm(last accessed January 2012).
3. Arbyn M, Castellsagué X, de Sanjosé S, Bruni L, Saraiya M, Bray F, et al. Worldwide burden of cervical cancer in 2008. Ann Oncol 2011;22(12):2675-86.
4. Lazcano-Ponce E, Lorincz AT, Cruz-Valdez A, Salmerón J, Uribe P, Velasco-Mondragón E, et al. Self collection of vaginal specimens for human papillomavirus testing in cervical cancer prevention (MARCH): a communitybased randomised controlled trial. Lancet 2011;378(9806):1868-73.
5. RHO Cervical Cancer. Cervical Cancer Prevention Action Planner. Available at: http://www.rho.org/actionplanner.htm(last accessed January 2012).
6. PATH. Cervical cancer project in Vietnam, 2011. Available at: http://www.path.org/publications/files/CPvietnamcxcaprojviet.pdf(last accessed January 2012).
7. Teodoroiu R, Murgea N. A model intervention for early detection and prevention of cervical cancer: An innovative parnership in Romania, 2007. Available at: http://pdf.usaid.gov/pdfdocs/PNADM198.pdf(last accessed March 2011).
8. Cervical Cancer Action. Progress in cervical cancer prevention: The CCA Report Card, 2011. Available at: http://www.cervicalcanceraction.org/pubs/pubs.php(last accessed December 2011).
9. Murray M. Progress in preventing cervical cancer: Updated evidence on vaccination and screening. Outlook 2010;27(2):1-12. Available at: http://www.rho.org/files/PATHoutlook272.pdf(last accessed June 2012).
10. Murillo R, Wiesner C, Cendales R, Pineros M, Tovar S. Comprehensive evaluation of cervical cancer screening programs: the case of Colombia. Instituto Nacional de Salud Pública de Mexico 2011;53:469-77.
11. Murillo R, Luna J, Gamboa O, Osorio E, Borilla J, Cendales R, et al. Cervical cancer screening with naked-eye visual inspection in Colombia. Int J Gynaecol Obstet 2010;109:230-4.
12. Franco EL, Mahmud SM, Tota J, Ferenczy A, Coutlée F. The expected impact of HPV vaccination on the accuracy of cervical cancer screening: the need for a paradigm change. Arch Med Res 2009;40(6):478-85.
13. Sankaranarayanan R, Nene BM, Shastri SS, Jayant K, Muwonge R, Budukh AM, et al. HPV Screening for cervical cancer in rural India. N Engl J Med 2009;360:1385-94.
14. Qiao YL, Sellors JW, Eder PS, Bao Y, Lim JM, Zhao F, et al. A new HPV-DNA test for cervical-cancer screening in developing regions: a cross-sectional study of clinical accuracy in rural China. Lancet Oncol 2008;9:929-36.
15. Qiagen. The careHPVTM Test. Available at:http://www.qiagen.com/about/whoweare/qiagencares/the-carehpv-test.pdf(last accessed January 2012).
16. Zhao FH, Jeronimo J, Paul P, Schweizer J, Chen W, Bai P, et al. Performance of HPV E6 test for detection of cervical neoplasia. In: Presented at: 27th International Papillomavirus Conference and Clinical Workshop. 2011.
17. Mwanahamuntu MH, Sahasrabuddhe VV, Kapambwe S, Pfaendler KS, Chibwesha C, Mkumba G, et al. Advancing cervical cancer prevention initiatives in resource constrained settings: Insights from the cervical cancer prevention program in Zambia. PLoS Med 17 05 2011;8(5):e1001032.
18. Centers for Disease Control Prevention. Ten great public health achievements - United-States 1900-1999. MMWR 1999;48(12):241-3.
19. TechNet 21. Global HPV vaccine licensure status: June 2011. Available at: http://www.technet21.org/index.php/documents/view-document-details/1286-global-hpv-vaccine-licensure-status-june-2011.html(last accessed January 2012).
20. Joura EA, Garland SM, Paavonen J, Ferris DG, Perez G, Ault KA, et al. Effect of the human papillomavirus (HPV) quadrivalent vaccine in a subgroup of women with cervical and vulval disease: retrospective pooled analysis of trial data. BMJ 2012;344:e1401.
21. Kreimer AR, Rodriguez AC, Hildesheim A, Herrero R, Porras C, Schiffman M, et al. Proof-of-principle evaluation of the efficacy of fewer than three doses of a bivalent HPV16/18 vaccine. J Natl Cancer Inst 2011;103(19):1444-51.
22. Singh Y, Shah A, Singh M, Verma S, Srestha BM, Vaidya P, et al. Human papilloma virus vaccination in Nepal: An initial experience. Asian Pac J Cancer Prev 2010;11(3):615-7.
23. LaMontagne S, Barge S, Le NT, Mugisha E, Penny ME, Gandhi S, et al. Human papillomavirus vaccine delivery strategies that achieved high coverage in low- and middle-income countries. Bull World Health Organ 2011;89(11), 821-30B.
24. PATH, Instituto de Investigaciòn Nutricional (IIN), Ministerio de Salud (MINSA) de Peru, Estrategia Sanitaria Nacional de Immunizaciones (ESNI). HPV vaccination in Latin America: Lessons learned from a pilot program in Peru. December, 2010. Available at: http://www.path.org/publications/files/RHhpvlessonslearnedperues.pdf(last accessed June 2012).
25. Penny M, Bartolini R, Mosqueira NR. Strategies to vaccinate against cancer of the cervix: feasibility of a school-based HPV vaccination program in Peru. Vaccine 2011;29(31):5022-30.
26. RHO Cervical Cancer. Cervical cancer prevention: Practical experience from PATH. Available at: http://www.rho.org/HPV-practical-experience.htm (last accessed January 2012).
27. Harries J, Moodley J, Barone MA, Mall S, Sinanovic E. Preparing for HPV vaccination in South Africa: Key challenges and opinions. Vaccine 2009;27: 38-44.
28. The Millenium Development Goals Report 2010. United Nations. New York, USA. Available at: http://www.un.org/millenniumgoals/pdf/MDG%20Report%202010%20En%20r15%20-low%20res%2020100615%20-.pdf (last accessed June 2012).
29. Giuliano AR, Salmon D. The case for a gender-neutral (universal) human papillomavirus vaccination policy in the United States: Point. Cancer Epidemiol Biomarkers Prev 2008;17:805-8.
30. Department of Immunization Vaccines and Biologicals. Report of the meeting on HPV vaccine coverage and impact monitoring, 16-17 November 2009. Geneva, Switzerland: World Health Organization, 2010.
31. World Health Organization. Immunization safety. Available at: http://www.who.int/immunizationsafety/en/(last accessed May 2012).
32. Weekly Epidemiological Record 2009;15:117-32. Available at: http://www.who.int/wer/2009/wer8415.pdf(last accessed June 2012).
33. Read TRH, Hocking JS, Chen MY, Donovan B, Bradshaw CS, Fairley CK. The near disappearance of genital warts in young women 4 years after commencing a national human papillomavirus (HPV) vaccination programme. Sex Transm Infect 2011;87(7):544-7.
34. Bauer HM, Wright G, Chow J. Evidence of human papillomavirus vaccine effectiveness in reducing genital warts: an analysis of California public family planning administrative claims data, 2007-2010. Am J Public Health 2012 May;102(5):833-5.
35. World Health Organization. WHO HPV Laboratory Network. Available at: http://www.who.int/biologicals/areas/vaccines/hpvlabnet/en/index.html(last accessed January 2012).
36. Franceschi S, Herrero R, Clifford GM, Snijders PJ, Arslan A, Anh PT, et al. Variations in the age-specific curves of human papillomavirus prevalence in women worldwide. Int J Cancer 2006;119(11):2677-84.
37. Wabinga H, Parkin DM, Nambooze S, Amero J. Cancer survival in Kampala, Uganda, 1993-1997. IARC Sci Publ 2011;162:243-7.
38. Basu P, Nessa A, Majid M, Rahman JN, Ahmed T. Evaluation of the National Cervical Cancer Screening Programme of Bangladesh and the formulation of quality assurance guidelines. J Fam Plann Reprod Health Care 2010;36(3): 131-4.
39. Suarez E, Prieto M. Cervical cancer: the Chilean perspective. Figo 26th Annual Report on the results of treatment in gynecological cancer. Int J Gynaecol Obstet 2006;95(Suppl 1):S235-8.
40. Murillo R, Almonte M, Pereira A, Ferrer E, Gamboa OA, Jerónimo J, et al. Cervical cancer screening programs in Latin America and the Caribbean. Vaccine 2008;26(Supplement 11):L37-48.
41. Ottawa Charter for Health Promotion. World Health Organization. First International Conference on Health Promotion. Ottawa, 17-21 November, 1986. Available at: http://www.who.int/healthpromotion/milestonesottawa.pdf(last accessed June 2012).
42. PATH. Report of an African regional meeting on cervical cancer. Kampala, Uganda. Improved cervical cancer prevention: Planning now for a better future. 14-15 September, 2010. Available at: http://www.rho.org/files/PATHAfricacxcaconfreport2010.pdf(last accessed June 2012).
43. Yothasamut J, Putchong C, Sirisamutr T, Teerawattananon Y, Tantivess S. Scaling up cervical cancer screening in the midst of human papillomavirus vaccination advocacy in Thailand. BMC Health Serv Res 2010;10(Suppl 1):S5.
44. Bishop A, Kovtun A, Okromeshko S, Karpilovskaya S, Suprun N. Lives renewed: the emergence of a breast cancer survivor movement in Ukraine. Reprod Health Matters 2001;9(18):126-34.
45. PATH. Implementing HPV vaccination programs: Practical experience from PATH. 2011. Available at: http://www.rho.org/files/PATHHPV-implementing-HPV-vaccination2011.pdf(last accessed June 2012).
46. Ruiz JG, Mintzer MJ, Leipzig RM. The impact of E-learning in medical education. Acad Med 2006;81(3):207-12.
47. Bayanbileg S. Cervical cancer prevention: the Mongolia experience with telemedicine. In: Presented at: Global Workshop on Programming Guidance for Prevention of Cervical Cancer. 2010.
48. Tsedmaa B, Shinetugs B, Genden P, Baigal G, Munlhbayar Ch, Enktuya S, et al. Telemedicine model of consultation for cervical cancer prevention. In: Presented at: 26th International Papillomavirus Conference & Clinical and Public Health Workshops. 2010.
49. RHO Cervical Cancer. Statement by the First Ladies of Ghana, Nigerm South Africa, Swaziland, Uganda, Zambia and The Gambia: A call for the greater focus and investment in adressing women's cancer. RHO Cervical Cancer. Available at: www.rho.org/files/AfricanFirstLadiesAccrastatement2010.pdf(last accessed January 2012).
50. World Health Organization. The Globocan project. Globocan 2008. Available at: http://globocan.iarc.fr/(last accessed January 2012).